![Frontiers | A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects Frontiers | A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects](https://www.frontiersin.org/files/Articles/646171/fphar-12-646171-HTML-r2/image_m/fphar-12-646171-g001.jpg)
Frontiers | A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects
![POS0950 LONG-TERM FOLLOW-UP OF STARTING AND SWITCHING FROM ORIGINAL ADALIMUMAB TO ADALIMUMAB BIOSIMILAR: REAL-WORLD DATA IN AXIAL SPONDYLOARTHRITIS | Annals of the Rheumatic Diseases POS0950 LONG-TERM FOLLOW-UP OF STARTING AND SWITCHING FROM ORIGINAL ADALIMUMAB TO ADALIMUMAB BIOSIMILAR: REAL-WORLD DATA IN AXIAL SPONDYLOARTHRITIS | Annals of the Rheumatic Diseases](https://ard.bmj.com/content/annrheumdis/81/Suppl_1/780.1/F1.large.jpg)
POS0950 LONG-TERM FOLLOW-UP OF STARTING AND SWITCHING FROM ORIGINAL ADALIMUMAB TO ADALIMUMAB BIOSIMILAR: REAL-WORLD DATA IN AXIAL SPONDYLOARTHRITIS | Annals of the Rheumatic Diseases
![Frontiers | A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects Frontiers | A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects](https://www.frontiersin.org/files/MyHome%20Article%20Library/646171/646171_Thumb_400.jpg)
Frontiers | A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects
![Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis | Clinical Pharmacokinetics Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis | Clinical Pharmacokinetics](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs40262-023-01221-x/MediaObjects/40262_2023_1221_Fig2_HTML.png)
Assessing the Impact of Immunogenicity and Improving Prediction of Trough Concentrations: Population Pharmacokinetic Modeling of Adalimumab in Patients with Crohn's Disease and Ulcerative Colitis | Clinical Pharmacokinetics
![Pharmaceutics | Free Full-Text | Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting Pharmaceutics | Free Full-Text | Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting](https://pub.mdpi-res.com/pharmaceutics/pharmaceutics-14-00352/article_deploy/html/images/pharmaceutics-14-00352-ag.png?1644565531)
Pharmaceutics | Free Full-Text | Adalimumab Decorated Nanoparticles Enhance Antibody Stability and Therapeutic Outcome in Epithelial Colitis Targeting
![Kaplan-Meier curves of time to ADA discontinuation in patients in the... | Download Scientific Diagram Kaplan-Meier curves of time to ADA discontinuation in patients in the... | Download Scientific Diagram](https://www.researchgate.net/publication/353151977/figure/fig1/AS:1044110987247616@1625946866011/Kaplan-Meier-curves-of-time-to-ADA-discontinuation-in-patients-in-the-AAA-negative-group.png)
Kaplan-Meier curves of time to ADA discontinuation in patients in the... | Download Scientific Diagram
![Anti‐TNF treatment negatively regulates human CD4+ T‐cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype - Povoleri - 2020 - European Journal of Immunology - Wiley Online Library Anti‐TNF treatment negatively regulates human CD4+ T‐cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype - Povoleri - 2020 - European Journal of Immunology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/c9a2bfc1-7cf0-4d10-9f50-5019ec1969cc/eji4653-fig-0005-m.jpg)
Anti‐TNF treatment negatively regulates human CD4+ T‐cell activation and maturation in vitro, but does not confer an anergic or suppressive phenotype - Povoleri - 2020 - European Journal of Immunology - Wiley Online Library
![Co-formulations of adalimumab with hyaluronic acid/polyvinylpyrrolidone to combine intraarticular drug delivery and viscosupplementation - ScienceDirect Co-formulations of adalimumab with hyaluronic acid/polyvinylpyrrolidone to combine intraarticular drug delivery and viscosupplementation - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0939641122001199-ga1.jpg)
Co-formulations of adalimumab with hyaluronic acid/polyvinylpyrrolidone to combine intraarticular drug delivery and viscosupplementation - ScienceDirect
![Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry | The Journal of Rheumatology Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry | The Journal of Rheumatology](https://www.jrheum.org/content/jrheum/47/7/959/F1.medium.gif)
Longterm, Real-world Safety of Adalimumab in Rheumatoid Arthritis: Analysis of a Prospective US-based Registry | The Journal of Rheumatology
![Rates of adalimumab (ADA) discontinuation according to the quartiles of... | Download Scientific Diagram Rates of adalimumab (ADA) discontinuation according to the quartiles of... | Download Scientific Diagram](https://www.researchgate.net/publication/351006741/figure/fig2/AS:11431281173610270@1688995526237/Rates-of-adalimumab-ADA-discontinuation-according-to-the-quartiles-of-antibody-levels.png)
Rates of adalimumab (ADA) discontinuation according to the quartiles of... | Download Scientific Diagram
![Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis | Scientific Reports Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis | Scientific Reports](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41598-022-08682-3/MediaObjects/41598_2022_8682_Fig1_HTML.png)
Assessment of immunogenicity and drug activity in patient sera by flow-induced dispersion analysis | Scientific Reports
![Half of adalimumab patients did not give consent for biosimilar switch, survey reveals - The Pharmaceutical Journal Half of adalimumab patients did not give consent for biosimilar switch, survey reveals - The Pharmaceutical Journal](https://pharmaceutical-journal.com/wp-content/uploads/2022/02/humira-scaled-e1645704431602.jpg)